Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agenus Inc. stock logo
AGEN
Agenus
$4.78
-7.0%
$3.39
$1.38
$18.74
$128.86M1.43664,377 shs645,662 shs
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$9.97
-3.1%
$9.51
$5.92
$11.31
$2.17B1.113.04 million shs3.90 million shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$53.11
-1.5%
$57.12
$42.01
$70.51
$6.65B1.191.64 million shs1.63 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$6.49
-7.7%
$6.72
$5.01
$17.81
$1.12B2.86.52 million shs8.73 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agenus Inc. stock logo
AGEN
Agenus
+9.36%-7.39%+47.70%+197.11%-66.75%
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
-0.77%-7.38%+0.49%+34.69%+66.77%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
-0.11%-0.85%+3.65%-13.78%+8.93%
Novavax, Inc. stock logo
NVAX
Novavax
+1.30%-5.13%+4.46%-11.57%-51.18%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Agenus Inc. stock logo
AGEN
Agenus
4.0211 of 5 stars
3.23.00.04.62.11.70.6
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
4.3359 of 5 stars
4.41.00.04.22.81.70.6
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
4.8626 of 5 stars
3.12.00.04.43.02.54.4
Novavax, Inc. stock logo
NVAX
Novavax
4.5341 of 5 stars
3.12.00.04.72.70.83.1
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agenus Inc. stock logo
AGEN
Agenus
2.33
Hold$14.00192.89% Upside
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
2.89
Moderate Buy$16.5666.05% Upside
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.17
Hold$61.9016.55% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.29
Hold$17.00161.94% Upside

Current Analyst Ratings Breakdown

Latest BCRX, AGEN, NVAX, and HALO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Novavax, Inc. stock logo
NVAX
Novavax
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSell$6.00
6/4/2025
Agenus Inc. stock logo
AGEN
Agenus
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$4.00 ➝ $6.00
6/4/2025
Agenus Inc. stock logo
AGEN
Agenus
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$25.00
5/29/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$72.00
5/19/2025
Novavax, Inc. stock logo
NVAX
Novavax
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/14/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$73.00 ➝ $62.00
5/13/2025
Agenus Inc. stock logo
AGEN
Agenus
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
5/13/2025
Agenus Inc. stock logo
AGEN
Agenus
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$3.00 ➝ $4.00
5/13/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeHold ➝ Strong Sell
5/13/2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeMarket Perform ➝ Underperform$47.00
5/9/2025
Novavax, Inc. stock logo
NVAX
Novavax
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$9.00 ➝ $7.00
(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agenus Inc. stock logo
AGEN
Agenus
$103.46M1.27N/AN/A($13.06) per share-0.37
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
$450.71M4.63N/AN/A($2.30) per share-4.33
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.02B6.45$4.58 per share11.60$2.86 per share18.57
Novavax, Inc. stock logo
NVAX
Novavax
$682.16M1.54N/AN/A($3.89) per share-1.67
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agenus Inc. stock logo
AGEN
Agenus
-$227.21M-$8.67N/AN/AN/A-196.12%N/A-82.33%8/6/2025 (Estimated)
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
-$88.88M-$0.26N/AN/A2.33-10.62%N/A-11.06%8/4/2025 (Estimated)
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$444.09M$3.7614.138.540.3644.76%136.91%26.05%8/5/2025 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
-$187.50M$2.652.4581.130.0838.14%-115.51%29.99%8/14/2025 (Estimated)

Latest BCRX, AGEN, NVAX, and HALO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Agenus Inc. stock logo
AGEN
Agenus
-$1.61-$1.03+$0.58-$1.03$26.38 million$24.07 million
5/8/2025Q1 2025
Novavax, Inc. stock logo
NVAX
Novavax
$0.71$2.93+$2.22$2.93$204.08 million$666.66 million
5/6/2025Q1 2025
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$0.98$1.11+$0.13$0.93$231.21 million$264.86 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Agenus Inc. stock logo
AGEN
Agenus
N/AN/AN/AN/AN/A
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/AN/AN/AN/AN/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agenus Inc. stock logo
AGEN
Agenus
N/A
0.11
0.11
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
N/A
2.93
2.88
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
3.13
8.39
7.30
Novavax, Inc. stock logo
NVAX
Novavax
N/A
2.06
2.03

Institutional Ownership

CompanyInstitutional Ownership
Agenus Inc. stock logo
AGEN
Agenus
61.46%
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
85.88%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
97.79%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%

Insider Ownership

CompanyInsider Ownership
Agenus Inc. stock logo
AGEN
Agenus
5.50%
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
4.80%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.90%
Novavax, Inc. stock logo
NVAX
Novavax
1.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Agenus Inc. stock logo
AGEN
Agenus
44027.42 million25.91 millionOptionable
BioCryst Pharmaceuticals, Inc. stock logo
BCRX
BioCryst Pharmaceuticals
530209.25 million199.21 millionOptionable
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
390123.22 million119.65 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990161.97 million160.35 millionOptionable

Recent News About These Companies

Novavax, Inc. stock logo
Novavax (NASDAQ:NVAX) Shares Gap Down - Should You Sell?
Novavax: New Vaccine, Same Old Story - Still A Sell

New MarketBeat Followers Over Time

Media Sentiment Over Time

Agenus stock logo

Agenus NASDAQ:AGEN

$4.78 -0.36 (-7.00%)
Closing price 04:00 PM Eastern
Extended Trading
$4.75 -0.03 (-0.63%)
As of 06:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

BioCryst Pharmaceuticals stock logo

BioCryst Pharmaceuticals NASDAQ:BCRX

$9.97 -0.32 (-3.11%)
Closing price 04:00 PM Eastern
Extended Trading
$10.05 +0.08 (+0.81%)
As of 07:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Halozyme Therapeutics stock logo

Halozyme Therapeutics NASDAQ:HALO

$53.11 -0.81 (-1.50%)
Closing price 04:00 PM Eastern
Extended Trading
$53.20 +0.09 (+0.17%)
As of 05:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

Novavax stock logo

Novavax NASDAQ:NVAX

$6.49 -0.54 (-7.68%)
Closing price 04:00 PM Eastern
Extended Trading
$6.52 +0.03 (+0.46%)
As of 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.